Agena granted EUA for SARS-CoV-2 panel

Create PDF

December 2020—Agena Bioscience’s MassArray SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted emergency use authorization from the FDA.

Clinical laboratories can process thousands of samples a day for less than $10 per sample running the assay on one Mass­Array instrument, the company says.

With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability.